| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.26 | 9e-14 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-10 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.22 | 3e-05 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 3e-05 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.2 | 7e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |